A gene-expression profiling score for outcome prediction disease in patients with follicular lymphoma: a retrospective analysis on three international cohorts

[1]  S. Swerdlow.  WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues , 2017 .

[2]  R. Bende,et al.  B-Lymphoblastic Lymphomas Evolving from Follicular Lymphomas Co-Express Surrogate Light Chains and Mutated Gamma Heavy Chains. , 2016, The American journal of pathology.

[3]  J. Cerhan,et al.  Early event status informs subsequent outcome in newly diagnosed follicular lymphoma , 2016, American journal of hematology.

[4]  A. Rosenwald,et al.  Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy. , 2016, Blood.

[5]  Robert Kridel,et al.  Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. , 2015, The Lancet. Oncology.

[6]  J. Cerhan,et al.  Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  R. Gascoyne,et al.  The Prognostic Impact of CD163-Positive Macrophages in Follicular Lymphoma: A Study from the BC Cancer Agency and the Lymphoma Study Association , 2015, Clinical Cancer Research.

[8]  S. Ansell,et al.  Therapeutic targeting of microenvironment in follicular lymphoma. , 2014, Hematology. American Society of Hematology. Education Program.

[9]  B. Nadel,et al.  Germinal center reentries of BCL2-overexpressing B cells drive follicular lymphoma progression. , 2014, The Journal of clinical investigation.

[10]  A. Rosenwald,et al.  The reliability of immunohistochemical analysis of the tumor microenvironment in follicular lymphoma: a validation study from the Lunenburg Lymphoma Biomarker Consortium , 2014, Haematologica.

[11]  R. Houot,et al.  Long-term follow up of the FL2000 study comparing CHVP-interferon to CHVP-interferon plus rituximab in follicular lymphoma , 2013, Haematologica.

[12]  E. Kimby,et al.  ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  P. Deloukas,et al.  Integrating Genome-Wide Genetic Variations and Monocyte Expression Data Reveals Trans-Regulated Gene Modules in Humans , 2011, PLoS genetics.

[14]  D. de Jong,et al.  The microenvironment in follicular lymphoma. , 2011, Best practice & research. Clinical haematology.

[15]  M. Pencina,et al.  On the C‐statistics for evaluating overall adequacy of risk prediction procedures with censored survival data , 2011, Statistics in medicine.

[16]  L. Waldron,et al.  mRNA transcript quantification in archival samples using multiplexed, color-coded probes , 2011, BMC biotechnology.

[17]  Andrew Lister,et al.  Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial , 2011, The Lancet.

[18]  J. D. Vos,et al.  Follicular lymphoma cell niche: identification of a preeminent IL-4-dependent TFH–B cell axis , 2009, Leukemia.

[19]  R. Gascoyne,et al.  Prognostic factors in follicular lymphoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Babak Shahbaba,et al.  A pluripotency signature predicts histologic transformation and influences survival in follicular lymphoma patients. , 2009, Blood.

[21]  Giovanni Martinelli,et al.  Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Daphne de Jong,et al.  Impact of the tumor microenvironment on prognosis in follicular lymphoma is dependent on specific treatment protocols , 2009, Haematologica.

[23]  Jennifer L. Osborn,et al.  Direct multiplexed measurement of gene expression with color-coded probe pairs , 2008, Nature Biotechnology.

[24]  G. Salles,et al.  High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  M. Karjalainen‐Lindsberg,et al.  A High Tumor-Associated Macrophage Content Predicts Favorable Outcome in Follicular Lymphoma Patients Treated with Rituximab and Cyclophosphamide-Doxorubicin-Vincristine-Prednisone , 2007, Clinical Cancer Research.

[26]  L. Staudt,et al.  A library of gene expression signatures to illuminate normal and pathological lymphoid biology , 2006, Immunological reviews.

[27]  P. Solal-Céligny,et al.  Follicular lymphoma international prognostic index , 2006, Blood.

[28]  L. Staudt,et al.  Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. , 2004, The New England journal of medicine.

[29]  J. Armitage,et al.  Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  Berthold Lausen,et al.  Maximally selected rank statistics , 1992 .